zileuton has been researched along with (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balter, M; Boulet, LP; Cairns, CB; Löfdahl, CG; O'Connor, BJ; Szczeklik, A | 1 |
1 trial(s) available for zileuton and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
| Article | Year |
|---|---|
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Beclomethasone; Double-Blind Method; Drug Therapy, Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Hydroxyurea; Middle Aged; Peak Expiratory Flow Rate; Severity of Illness Index; Single-Blind Method | 2007 |